Drug manufacturers have been scrambling to develop new and cheaper versions of their drug-delivery devices, and that has led to a surge in the use of new drugs in Europe and other countries.
But it has also resulted in a massive supply glut in the United States, where companies are being forced to compete with each other to get the drugs to patients.
The Drug Enforcement Administration’s National Pharmaceutical Product Data Center says the U.S. imported $3.2 billion worth of new drug products last year.
That’s more than triple the amount of drug-related imports the agency said it was able to track in 2015.
“It’s just going to keep going and go up,” said Robert Stowe, a senior fellow at the libertarian Cato Institute.
“That’s the thing that’s driving this global crisis of supply.
The world is now in a position where drugs are becoming less and less accessible.”
A shortage of drugs can be frustrating for patients, as they wait months to get their drugs.
They often can’t afford to pay for a new drug if they have to buy their medication over the counter, or even to visit a doctor to take a prescription.
Some people also find it hard to get a new medication approved for them.
A study published this month by the National Bureau of Economic Research estimated that the U., as a whole, spent about $10 billion a year on prescription drugs in the U, which is less than half the roughly $70 billion the country spent annually on all other prescription drugs.
The problem is even more acute for people in developing countries.
Many developing countries lack the pharmaceutical companies to produce drugs, making it even harder for them to access them, said Mark Hurd, director of the Center for Global Health at George Mason University.
“We need the world to step up to the plate and help us solve the problems of access to medicines in developing nations,” Hurd said.
In the U.-developed world, the lack of new medicines has been a major driver of a massive rise in deaths related to infections and deaths from infectious diseases, including HIV and tuberculosis.
That means a lot of money is being spent trying to develop ways to treat diseases that are spreading.
Some countries are also investing heavily in drug production to try to combat what they view as a growing problem of overprescribing.
The U.K. government is spending $5.6 billion a month on drug-production and research to fight drug shortages.
China is investing $8.4 billion a week on research to try and develop a cheaper, more effective, and more efficient drug-approval system.
“This is a very, very complicated problem that requires a lot more effort than we’ve seen to date,” said David Nutt, the former chairman of the U-K.
Health Policy Committee and now a senior adviser at the World Health Organization.
“I think it’s the greatest challenge we’ve ever faced in human history, because we’ve got to do something different.”
A global crackdown On Tuesday, the European Union’s top drug official said Europe’s drug companies must do more to fight the rise of drug shortages, saying they should invest in research and development and spend more to develop and distribute new medicines.
“The drugs industry must be able to offer the medicines it needs to be able survive,” Jose Manuel Barroso, the director general of the European Medicines Agency, said at a news conference in Brussels.
“And we must be more willing to spend on medicines that can be more effective.”
He said the agency would also “consider” measures to help the European pharmaceutical industry in other countries that have struggled to get drugs into the market.
But many pharmaceutical companies are skeptical of his suggestions.
“There’s a long-standing and deep suspicion about our regulatory system and the EU itself,” said James D’Antonio, chief executive of British pharmaceutical company GlaxoSmithKline.
“People have been waiting for this for so long.
They’ve been waiting since the 1930s for us to do this.
And that’s why I think we’ve been so slow.”